Mu-opioid receptor knockout on Foxp2-expressing neurons reduces aversion-resistant alcohol drinking
Pharmacology Biochemistry and Behavior · 2025
DOI: 10.1016/j.pbb.2024.173932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025. Verfasst von Harrison M Carvour und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology and Center for Neuroscience and Behavior, Miami University, Oxford, OH, USA. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Alcohol Drinking, Forkhead Transcription Factors, Neurons. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health.
Abstract (Originalsprache)
Mu-opioid receptors (MORs) in the amygdala and striatum are important in addictive and rewarding behaviors. The transcription factor Foxp2 is a genetic marker of intercalated (ITC) cells in the amygdala and a subset of striatal medium spiny neurons (MSNs), both of which express MORs in wild-type mice and are neuronal subpopulations of potential relevance to alcohol-drinking behaviors. For the current series of studies, we characterized the behavior of mice with genetic deletion of the MOR gene Oprm1 in Foxp2-expressing neurons (Foxp2-Cre/Oprm1fl/fl). Male and female Foxp2-Cre/Oprm1fl/fl mice were generated and heterozygous Cre+ (knockout) and homozygous Cre- (control) animals were tested for aversion-resistant alcohol consumption using an intermittent access (IA) task, operant responding for a sucrose reward, conditioned place aversion (CPA) to morphine withdrawal, and locomotor sensitization to morphine. The results demonstrate that deletion of MOR on Foxp2-expressing neurons renders mice more sensitive to quinine-adulterated alcohol. Mice with the deletion (vs. Cre- controls) also consumed less alcohol during the final sessions of the IA task, were less active at baseline and following morphine injection, and there was a trend toward less responding for sucrose under an FR3 schedule. Foxp2-MOR deletion did not impair the ability to learn to respond for reward or develop a conditioned aversion to morphine withdrawal. Together, these investigations demonstrate that Foxp2-expressing neurons may be involved in escalation of alcohol consumption and the development of compulsive-like alcohol drinking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology and Center for Neuroscience and Behavior, Miami University, Oxford, OH, USA.
- Department of Psychology and Center for Neuroscience and Behavior, Miami University, Oxford, OH, USA. Electronic address: aradke@miamioh.edu.
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
- National Institutes of Health
- Buffalo State College - Office of Undergraduate Research
- University of Miami
Zitieren
APA
Carvour, H. M., Roemer, C. A. E. G., Underwood, D. P., Padilla, E. S., Sandoval, O., Robertson, M., Miller, M., Parsadanyan, N., Perry, T. W., & Radke, A. K. (2025). Mu-opioid receptor knockout on Foxp2-expressing neurons reduces aversion-resistant alcohol drinking. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2024.173932
Vancouver
Carvour HM, Roemer CAEG, Underwood DP, Padilla ES, Sandoval O, Robertson M, et al. Mu-opioid receptor knockout on Foxp2-expressing neurons reduces aversion-resistant alcohol drinking. Pharmacology Biochemistry and Behavior. 2025. doi:10.1016/j.pbb.2024.173932
BibTeX
@article{Carvour2025,
author = {Carvour, Harrison M and Roemer, Charlotte A E G and Underwood, D'Erick P and Padilla, Edith S and Sandoval, Oscar and Robertson, Megan and Miller, Mallory and Parsadanyan, Natella and Perry, Thomas W and Radke, Anna K},
title = {Mu-opioid receptor knockout on Foxp2-expressing neurons reduces aversion-resistant alcohol drinking},
journal = {Pharmacology Biochemistry and Behavior},
year = {2025},
doi = {10.1016/j.pbb.2024.173932}
}
EUVIMED